Get startedLog in
    Picture of Adial Pharmaceuticals logo

    ADIL — Adial Pharmaceuticals News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMicro CapMomentum Trap
    All News

    Brief: Adial Pharmaceuticals Announces Topline Results For Onward Phase 3 Trial For Ad04 In Patients With Alcohol Use Disorder

    Picture of Adial Pharmaceuticals logoAdial Pharmaceuticals
    20/07/2022 13:11
    July 20 (Reuters) - Adial Pharmaceuticals Inc  ADIL.O :
    * ADIAL PHARMACEUTICALS ANNOUNCES TOPLINE RESULTS FOR
ONWARD™
PHASE 3 TRIAL FOR AD04 IN PATIENTS WITH ALCOHOL USE DISORDER
    * ADIAL PHARMACEUTICALS INC - COMPANY PLANS TO SUBMIT ONWARD
RESULTS TO BOTH EUROPEAN AND U.S. REGULATORY AGENCIES
    * ADIAL - AD04 ACHIEVED STATISTICALLY SIGNIFICANT MEAN
REDUCTION
IN HEAVY DRINKING DAYS AMONG PRE-SPECIFIED GROUP OF HEAVY
DRINKERS, COMPARED TO PLACEBO
    * ADIAL PHARMACEUTICALS INC - AD04 DEMONSTRATED
STATISTICALLY
SIGNIFICANT DIFFERENCE IN AUD SEVERITY, AS COMPARED TO PLACEBO
    * ADIAL PHARMACEUTICALS INC - AD04 ALSO SHOWED SAFETY AND
TOLERABILITY THAT COMPARED FAVORABLY TO PLACEBO

Source text for Eikon:  ID:nGNX8jFVMm 
Further company coverage:  ADIL.O 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Adial Pharmaceuticals

    See all news